For: | Wei YM, Wang XJ, Yang XD, Wang CS, Wang LL, Xu XY, Zhao GJ, Li B, Zhu DM, Wu Q, Shen YF. Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance. World J Psychiatry 2023; 13(11): 937-948 [PMID: 38073894 DOI: 10.5498/wjp.v13.i11.937] |
---|---|
URL: | https://www.wjgnet.com/2220-3206/full/v13/i11/937.htm |
Number | Citing Articles |
1 |
Clara Cavallotto, Stefania Chiappini, Alessio Mosca, Giacomo d’Andrea, Francesco Di Carlo, Tommaso Piro, Ottavia Susini, Giulia Stefanelli, Andrea Di Cesare, Valerio Ricci, Maria Pepe, Luigi Dattoli, Marco Di Nicola, Mauro Pettorruso, Giovanni Martinotti. Examining Lurasidone Efficacy in Patients with Schizophrenia Spectrum Illness and Concurrent Alcohol and Substance Use Disorder: A Prospective, Multicentric, Real-World Investigation. Journal of Clinical Medicine 2024; 13(8): 2206 doi: 10.3390/jcm13082206
|
2 |
Valerio Ricci, Domenico De Berardis, Giuseppe Maina. Third-Generation Antipsychotics and Lurasidone in the Treatment of Substance-Induced Psychoses: A Narrative Review. Healthcare 2024; 12(3): 339 doi: 10.3390/healthcare12030339
|